Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Samsung Medical Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Kineta Inc.
Silverback Therapeutics
Samsung Medical Center
Yonsei University
MultiVir, Inc.